Biocon Earnings Call Highlights Q4 FY21 | Yadnya Investment Academy

Published on 29 June 2021
.Views 5 .Comments 0

Share On

Financial Performance Quarter 4: BIOCON Valuation, BIOCON Company, BIOCON Analysis, BIOCON Analyst Report & BIOCON Annual Results

Revenue Growth for the quarter increased by 26% from 1621 Cr to 2044 Cr Year-on-year basis.
Revenue from Operations increased by 18% at 1839 Cr, driven majorly by 53% exponential growth in biosimilars business.
Gross R&D @12% of revenue being 136 Cr other than Syngene due to higher spending in novel biologics, biosimilars, and generics.
Net profit for the quarter stands at 257 Cr.
Valuation Gain due to ceding control of Bianca is 160 Cr
EBITDA margin excluding Bianca Valuation Gain stands at 26% compared to 24% Year on Year basis.
Core EBITDA Margin excluding Bianca Valuation Gain stands at 32% as against 29% Year on Year.
Net profit from continuing operations for the quarter declined to 97 Cr from 132 Cr last year.
Net profit margin excluding Bianca Valuation Gain declined from 8% to 5% in current quarter Year on Year basis.

The fiscal Year 2021 - BIOCON Stock Chart, BIOCON Stock Review, BIOCON Stock Market & BIOCON Share Value

Total Consolidated Revenues grew to ₹7,360 Cr, up by 14% compared to ₹6,462 Cr the previous year.
Revenue from Operations stands at ₹7,106 Cr, up by 13%.
Gross R&D spend stands at ₹627 Cr during the year, corresponding to 13% of revenues excluding Syngene.
Gross R&D spend increased 19% in FY 2021 from 527 Cr to 627 Cr compared to the previous year.
Forex loss of ₹9 Cr compared to a gain of ₹65 Cr in the previous year.
Growth in EBITDA at 8% for the year being ₹1,907 Cr.
EBITDA margin excluding Bianca Valuation Gain stands at 24%, in contrast to 27% last year.
Core EBITDA Margin excluding Bianca Valuation Gain stands at 32% against 33% in the previous year.
Net profit margin excluding Bianca Valuation Gain declined to 8% from 12% in the previous year.

Revenue by segments - BIOCON Value Research

Biosimilars have shown exponential growth in revenue of 53% in the 4th Quarter YOY basis. 21% growth has been reported as compared to the previous year, 2020
Generics Business has shown a tad bit of revenue growth of 3% in revenue on a quarter 4 YOY basis. However, the overall growth of 6% has been shown in the financial year as well.
The research business has shown revenue growth of 8% in Quarter 4 YoY basis. Overall Growth of 9% has also been recorded in the fiscal year.

Management Updates:

Other Updates: BIOCON Share Price India, BIOCON Dividend, BIOCON Stock Price & BIOCON Share Price History

The company has Received Market Authorization approval from European Commission for both biosimilar Insulin Aspart and biosimilar Bevacizumab developed in cooperation with Viatris
USFDA Approval has been granted in Generic Business for Everolimus used to treat renal cancer & rejection of organ transplant
Biocon has entered into a partnership with Libbs Farmaceutica in Brazil for diversification of Generics Business.
Syngene, the research business, has extended collaboration with BMS till 2030. The new agreement includes a 40% increase in scientists and an additional 50,000 sq. ft. of dedicated laboratory space.
In Q4FY21, Biocon ceded control over the Board of Directors and Operations of Bicara Therapeutics Inc. to operate independently under a US-based leadership team and raise funds to advance its development programs. As a result of this change, Bicara was classified as an Associate from a Subsidiary under IND-AS.

ABOUT INVEST YADNYA

We are the best website for ready-made portfolios. We are the Best Stock Advisory Service In India. Our stock-o-meter covers a very detailed analysis of companies. With best-managed portfolios, one can make sane investments. We have maintained a series of free financial eBooks which keeps you updated.